---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-25-000024"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T13:49:35.013213+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M

## Summary
- Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.
- FY24 consolidated revenue $661M (+12% YoY); net loss $79M (improved from $88M).
- Adjusted EBITDA FY24 positive $40M vs $3M in 2023, a 1,036% increase.
- FY2025 guidance: revenue $735-745M (11-13% growth); adjusted EBITDA $55-58M.
- Ninth consecutive quarter of double-digit revenue growth; NGS grew 34% in 2024.

## SEC filing metadata
- accession: 0001077183-25-000024
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000024/0001077183-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718325000024/neo-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-25-000024
- JSON: https://secwatch.observer/filing/0001077183-25-000024.json
- Plain text: https://secwatch.observer/filing/0001077183-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.